VBI Vaccines (NASDAQ:VBIV) issued its earnings results on Friday. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02), MarketWatch Earnings reports. The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.24 million. VBI Vaccines had a negative return on equity of 53.12% and a negative net margin of 6,175.95%.
VBIV traded down $0.12 during midday trading on Friday, hitting $2.05. 350,317 shares of the company were exchanged, compared to its average volume of 285,258. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 0.14. VBI Vaccines has a 1-year low of $1.64 and a 1-year high of $5.10.
A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Friday, September 28th. BMO Capital Markets cut their price target on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, July 27th. Finally, ValuEngine raised VBI Vaccines from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. VBI Vaccines currently has a consensus rating of “Hold” and a consensus target price of $8.63.
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Recommended Story: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.